{"title":"Immune Response Mechanisms in Haemophilia A.","authors":"Amina Abdelmageed, Clivia Lisowski, Janine Becker-Gotot","doi":"10.1055/a-2748-8775","DOIUrl":"https://doi.org/10.1055/a-2748-8775","url":null,"abstract":"<p><p>Haemophilia A (HA) is an X-linked bleeding disorder caused by the deficiency or dysfunction of coagulation factor VIII (FVIII). Substitution therapy with recombinant or plasma-derived FVIII effectively restores haemostasis but carries the risk of eliciting FVIII-specific neutralizing antibodies known as inhibitors. Inhibitor formation reflects the absence of central immune tolerance, driven by complex interactions among antigen-presenting cells, B cells and CD4 T cell subsets. Recent studies highlight the essential roles of T cell polarization, costimulatory signalling and cytokine networks in shaping the immunogenic or tolerogenic outcome of FVIII exposure. This review summarizes mechanistic insights into how distinct CD4 T cell subpopulations, including Th1, Th2, Th17, follicular helper (Tfh), follicular regulatory (Tfr) and regulatory T cells (Tregs), influence inhibitor development in HA. Furthermore, it discusses emerging immunological concepts and cellular pathways that could be targeted to achieve durable tolerance towards FVIII, with emphasis on translational strategies that align mechanistic understanding with clinical need.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"46 1","pages":"17-23"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HamostaseologiePub Date : 2026-02-01Epub Date: 2026-02-19DOI: 10.1055/a-2749-2763
Tobias Feige, Agnes Bosbach, Kim J Krott, Margitta Elvers
{"title":"Role of Platelets in Abdominal Aortic Aneurysm Formation and Progression: New Aspects from Experimental and Clinical Approaches.","authors":"Tobias Feige, Agnes Bosbach, Kim J Krott, Margitta Elvers","doi":"10.1055/a-2749-2763","DOIUrl":"https://doi.org/10.1055/a-2749-2763","url":null,"abstract":"<p><p>Abdominal aortic aneurysm (AAA) is a vascular disease with an atherosclerotic background resulting in progressive abdominal aortic dilation. The mechanisms of AAA progression include chronic inflammation within the aneurysm segment, reinforcing extracellular matrix degradation, and weakening of the aortic vessel wall. Platelets are essential mediators of hemostasis and play a dominant role in cardiovascular disease. Recent data suggest a pivotal role of platelets in AAA formation and progression by dysregulated platelet activation. These findings include a potential crosstalk of platelets with different cell types such as macrophages and fibroblasts, which amplifies the inflammatory response within the aortic tissue and promotes aortic wall stiffening. Experimental studies provided evidence for platelets to directly contribute to AAA formation and progression via the collagen receptor glycoprotein VI by promoting vascular inflammation, as well as aortic wall remodeling. Moreover, platelet and red blood cell interactions via the TSP-1-CD36 axis reinforces aneurysm formation via elevated procoagulant activity of both cells in experimental mice and AAA patients. Therefore, platelets and a platelet-mediated cellular crosstalk play a crucial role in AAA by promoting the development and progression of AAA. To date, no therapeutic treatment is available and surgical repair is the only option to prevent patients from aortic rupture. Thus, there is a strong need for an effective therapy to attenuate AAA progression. This review highlights the mechanisms of platelet activation and the relevance for the identification of new platelet-derived targets to develop a drug-based therapy for AAA patients.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"46 1","pages":"53-64"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146229936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HamostaseologiePub Date : 2026-02-01Epub Date: 2026-02-17DOI: 10.1055/a-2755-7600
Friedrich Reusswig, Carsten Deppermann
{"title":"The Role of Platelets Beyond Hemostasis.","authors":"Friedrich Reusswig, Carsten Deppermann","doi":"10.1055/a-2755-7600","DOIUrl":"https://doi.org/10.1055/a-2755-7600","url":null,"abstract":"<p><p>Platelets, small anucleate cells derived from megakaryocytes, are key drivers of hemostasis and thrombosis. There is accumulating evidence, however, that platelets play roles beyond thrombosis and hemostasis, especially in inflammation, infection, and tissue regeneration. They can recruit, stimulate, and modulate immune cells by direct interaction or via the release of soluble factors. During inflammation, platelets maintain vascular integrity in the lung, skin, and brain through interactions of their GPVI, CLEC-2, and GPIb receptors as well as factors released from α-granules and dense granules. They cooperate with monocytes and macrophages to fight bacteria in the bloodstream and in the liver where they accumulate on Kupffer cell-bacteria complexes to support pathogen destruction. Upon liver damage, platelets adhere to the liver sinusoids and release bioactive molecules like serotonin and fibrinogen to support reparative processes. Here, we provide a review of some of the multiple roles of platelets beyond their classical role in hemostasis.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"46 1","pages":"44-52"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146215077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HamostaseologiePub Date : 2026-01-30DOI: 10.1055/a-2773-1622
Fedor A Balabin, Sofia V Galkina, Ravilya Dzhamaliddinova, Leonid Vedernikov, Irina E Zhizhaikina, Ludmila G Zhukova, Ekaterina V Shamova, Mikhail Panteleev, Anastasia N Sveshnikova
{"title":"Heterogeneity of Single-platelet Calcium Responses to Activation.","authors":"Fedor A Balabin, Sofia V Galkina, Ravilya Dzhamaliddinova, Leonid Vedernikov, Irina E Zhizhaikina, Ludmila G Zhukova, Ekaterina V Shamova, Mikhail Panteleev, Anastasia N Sveshnikova","doi":"10.1055/a-2773-1622","DOIUrl":"https://doi.org/10.1055/a-2773-1622","url":null,"abstract":"<p><p>Cytosolic calcium oscillations play a central role in platelet activation. However, signaling heterogeneity between platelets of the same individual, or between individuals, is poorly characterized. We utilized total internal reflection fluorescence microscopy of calcium fluorophore-loaded, surface-attached human platelets to monitor single-platelet calcium responses to collagen, ADP, and thrombin. For all activation types in healthy adult donors, four types of platelet calcium dynamics (\"activation groups) were distinguished: (I) isolated spikes; (II) oscillations with a period of 3-10 s; (III) clusters of spikes following each other with calcium levels never returning to baseline; and (IV) a sustained high calcium level. The activation Groups I and II were predominant in the immobilized platelets of healthy adults (46 ± 22% and 33 ± 10%, respectively), with 18 ± 13% of platelets in Group III. Stimulation with ADP shifted the activation pattern, with Group I fraction falling to 15 ± 9% and Group III fraction rising to 43 ± 13% instead. For stimulation with ADP plus thrombin or collagen, Group III was predominant (71 ± 11% for thrombin, 46 ± 18% for collagen). A combination of all three agonists mainly produced Level III (69 ± 15%) and Level IV (18 ± 12%) platelets. Confocal microscopy revealed a gradual increase in all activation markers (including integrin activation, granule secretion, and spreading type) when one goes from Group I to Group IV. In the triple-negative breast cancer patients samples before therapy, the responses were shifted toward Group I indicating that their platelets were refractory. These results indicate the importance of platelet heterogeneity analysis and suggest a novel technique to investigate minor populations of refractory or hyperactive platelets.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HamostaseologiePub Date : 2026-01-27DOI: 10.1055/a-2781-8742
Meike Hoffmeister, Steffen Herzig, Alexander Schmidt, Jamil Hmida, Fabian Tomschi, Thomas Hilberg
{"title":"Extraarticular and Intraarticular Key Lesions in Knee Joints of Adult Persons with Hemophilia-A Case-Control Ultrasound Study.","authors":"Meike Hoffmeister, Steffen Herzig, Alexander Schmidt, Jamil Hmida, Fabian Tomschi, Thomas Hilberg","doi":"10.1055/a-2781-8742","DOIUrl":"https://doi.org/10.1055/a-2781-8742","url":null,"abstract":"<p><strong>Background: </strong>Persons with hemophilia (PwH) develop arthropathic changes due to recurrent hemarthroses. This study aimed to comprehensively investigate structural knee joint alterations in PwH, extended beyond synovitis and osteochondral abnormalities, and to compare findings with healthy controls (Con).</p><p><strong>Methods: </strong>Bilateral knee ultrasound examinations were performed in 36 male PwH (severe A: 30, B: 2; moderate A: 3, B: 1; mean age: 47.1 ± 12.0) and 39 age-matched Con (mean age: 47.7 ± 12.8). A total of 26 landmarks and tissues, including synovium, osteophytes, ligaments, tendons, and bursae, were assessed quantitatively or semi-quantitatively. Clinical joint status was classified using the Hemophilia Joint Health Score, distinguishing between minorly (PwH-MI) and majorly (PwH-MA) affected joints.</p><p><strong>Results: </strong>Synovium, osteophytes, ligaments, and bursae showed more pronounced alterations in PwH compared to Con. While the iliotibial band was slightly thicker in PwH (<i>p</i> = 0.023), the popliteus tendon (<i>p</i> = 0.001) and patellar tendon at the tibial insertion were significantly thinner. PwH-MA showed significant changes at all landmarks (<i>p</i> < 0.001), while PwH-MI demonstrated differences only in the lateral knee joint synovium (<i>p</i> = 0.006) compared to Con. Osteophytes and synovium were significantly thicker in PwH-MA than in PwH-MI.</p><p><strong>Conclusion: </strong>The findings highlight the importance of assessing periarticular structures in PwH, as changes may contribute to functional impairments such as gait deviations. Further research is required to clarify the clinical implications.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Hypofibrinolysis State Associated with the Dysfibrinogenemia Dusart is Mainly Related to the Altered Fibrin Clot Structure.","authors":"Rita Marchi, Éva Katona, Stéphane Durual, Emmanuel Demaistre, Philippe Savard, Alessandro Casini","doi":"10.1055/a-2739-3030","DOIUrl":"https://doi.org/10.1055/a-2739-3030","url":null,"abstract":"<p><p>The fibrinogen Dusart (p.Aα573Arg > Cys) is a dysfibrinogenemia associated with an increased risk of thrombosis. The aim of this study was to identify factors that could explain the hypofibrinolytic state associated with the Dusart mutation.The fibrin α2-antiplasmin (α2-AP) incorporation was quantified by a homemade enzyme-linked immunosorbent assay. The fibrin formation and lysis were studied by turbidity at 405 nm, and the global fibrinolytic capacity (GFC) with the Lysis timer device. The plasmin generation was assessed through an automated method. The clot growth was examined using Thrombodynamics. The clot structure was evaluated by measuring the permeation constant and scanning electron microscopy (SEM).The plasma levels of D-dimer, PAI-1, FXIII, PAP, and α2-AP were within the normal range, as was α2-AP incorporation into fibrin. By turbidity the patient's clots were almost transparent, and very resistant to fibrinolysis. The patient's GFC was 51 minutes compared with 45 minutes in control. The patient's endogenous plasmin potential and the peak plasmin were increased. The Thrombodynamics analysis revealed an increased lag time and a decreased initial velocity of patient's clot growth. The fibrin clot structure was characterized by a strong reduction in clot's flow (small pores size), and very thin fibers.The patient's procoagulant phenotype appears primarily driven by the formation of abnormally compact fibrin networks, leading to impaired perfusion and resistance to fibrinolysis, independent of any imbalance in fibrinolytic activators or inhibitors. These findings highlight the critical role of the fibrin clot structure in the thrombotic risk of this variant.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HamostaseologiePub Date : 2026-01-19DOI: 10.1055/a-2717-3413
Jens Müller, Martin Büchsel, Behnaz Pezeshkpoor, Heiko Rühl, Bernd Pötzsch, Claudia Klein, Georg Goldmann, Natascha Marquardt, Thilo Albert, Kerstin Herbst, Johannes Oldenburg
{"title":"On Factor VIII Assay Discrepancies in Post-infusion Samples Obtained from Patients Treated with Efanesoctocog Alfa.","authors":"Jens Müller, Martin Büchsel, Behnaz Pezeshkpoor, Heiko Rühl, Bernd Pötzsch, Claudia Klein, Georg Goldmann, Natascha Marquardt, Thilo Albert, Kerstin Herbst, Johannes Oldenburg","doi":"10.1055/a-2717-3413","DOIUrl":"https://doi.org/10.1055/a-2717-3413","url":null,"abstract":"<p><p>Efanesoctocog alfa (efa) is a recombinant coagulation factor VIII (FVIII) concentrate, engineered for improved extended half-life in hemophilia A treatment. Its design results in discrepancies in FVIII diagnostic tests, as has so far been demonstrated using spiked sample material (efa added to FVIII-deficient plasma). The aim of the present study was to evaluate FVIII assay discrepancies in post-infusion samples obtained from patients treated with efa. This retrospective analysis included 43 male patients on efa prophylaxis (26 on once weekly and 17 on twice weekly treatment scheme) summoned for determination of incremental recoveries. FVIII activity was measured at trough (3.5 or 7 days post-infusion) and peak levels (30 minutes post-infusion) using three diagnostic tests: two one-stage clotting assays (OSCAs) based on Actin FSL (AFSL) or Actin FS (AFS), and a chromogenic substrate assay (FVIII CSA). Incremental recoveries as determined by the recommended AFSL-based OSCA were found to be comparable between patient groups. At peak levels (64 to 214 IU/dL), comparable overestimation (1.9-fold) of plasma efa activity relative to Actin FSL-based OSCA was observed for both, the AFS-based OSCA and the FVIII CSA. In contrast, at trough levels (5 to 64 IU/dL), rate of overestimation relative to the AFSL-based OSCA results was found to be lower for the FVIII CSA (1.3-fold) when compared with the AFS-based OSCA (1.9-fold). Further analysis demonstrated different behavior of spiked and post-infusion samples within the FVIII CSA. Future studies will reveal underlying mechanisms and assess if drug-specific calibration will sufficiently correct for this phenomenon.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146004519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HamostaseologiePub Date : 2025-12-01Epub Date: 2024-03-11DOI: 10.1055/a-2238-4782
Nikica Sabljic, Mirjana Mitrovic, Nikola Pantic, Jecko Thachil
{"title":"Thrombosis in Acute Promyelocytic Leukemia: The Current Understanding.","authors":"Nikica Sabljic, Mirjana Mitrovic, Nikola Pantic, Jecko Thachil","doi":"10.1055/a-2238-4782","DOIUrl":"10.1055/a-2238-4782","url":null,"abstract":"<p><p>Despite enormous improvement in the management of patients with acute promyelocytic leukemia (APL), the distinctive coagulopathy observed at presentation in affected patients is often life-threatening. While hemorrhagic manifestations are well known and described in this setting, APL-related thromboses are underappreciated. Data regarding this complication are scarce showing variable incidence. Furthermore, risk factors for thrombosis are inconsistent and unreliable; so, differentiation of increased risk of hemorrhage from an increased thrombotic risk is quite difficult in the absence of adequate predictive scores. Besides, prophylactic use of anticoagulants and recombinant thrombomodulin are a matter of ongoing debate. Also, due to the common feature of thrombocytopenia and other hemorrhagic risks, patients with APL are excluded from trials analyzing anticoagulant prophylaxis in cancers; so, data from prospective trials are lacking. A detailed analysis of thrombotic risks in APL with the development of a reliable risk stratification model is needed to further improve the care of APL patients.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"457-464"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Novel Perspectives on Thrombopoietin Receptor Agonists Applications.","authors":"Christos Stafylidis, Dimitra Vlachopoulou, Stavroula Syriopoulou, Sevastianos Chatzidavid, Nora-Athina Viniou","doi":"10.1055/a-2250-9369","DOIUrl":"10.1055/a-2250-9369","url":null,"abstract":"<p><p>Second-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag, have been proved to be significant stimulators of megakaryopoiesis and, in the last decade, they have been incorporated in the treatment options against refractory immune thrombocytopenia in children and adults that do not respond to conventional therapy. Additionally, given their beneficial impact on hematopoiesis, they have successfully been applied in cases of non-immune thrombocytopenia, such as aplastic anemia, HCV-related thrombocytopenia, chronic liver disease, and most recently acute radiation syndrome. During the past years, a wide variety of clinical studies have been performed, in regard to the use of TPO-RAs in various thrombocytopenic settings, such as malignant hematology and hematopoietic stem cell transplantation, hereditary thrombocytopenias, and chemotherapy-treated patients with solid organ tumors. Although data indicate that TPO-RAs may be an effective and safe option for managing disease- or treatment-related thrombocytopenia in these patients, further research is needed to determine their efficacy and safety in these settings. Furthermore, recent studies have highlighted novel properties of TPO-RAs that render them as potential treatment candidates for reducing tumor burden or fighting infections. Herein, we discuss the potential novel applications of TPO-RAs and focus on data regarding their efficacy and safety in these contexts.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"465-481"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HamostaseologiePub Date : 2025-12-01Epub Date: 2024-03-01DOI: 10.1055/a-2238-4744
Mirjana Kovac, Milena Todorovic Balint, Marija Milenkovic, Dusica Basaric, Branko Tomic, Bela Balint, Vera Ignjatovic
{"title":"Assessment of Factor VIII Activity and D-Dimer Levels in the Post-COVID Period.","authors":"Mirjana Kovac, Milena Todorovic Balint, Marija Milenkovic, Dusica Basaric, Branko Tomic, Bela Balint, Vera Ignjatovic","doi":"10.1055/a-2238-4744","DOIUrl":"10.1055/a-2238-4744","url":null,"abstract":"<p><p>Changes in the hemostatic system during COVID infection lead to hypercoagulability. Numerous studies have evaluated hemostatic abnormalities in COVID patients during acute infection, in the period of hospitalization. However, the hemostatic status following hospital discharge has not been sufficiently assessed. Considering the importance of FVIII and D-dimer levels as markers for the assessment of thrombosis, our study aimed to evaluate changes in these markers, as well as the influence of patient's age and clinical presentation of COVID infection on those hemostatic markers in the post-COVID phase. This prospective study (July 2020 to December 2022) included 115 COVID patients, 68 (59%) with asymptomatic/mild and 47 (41%) with moderate/severe clinical presentation. Patient follow-up included laboratory evaluation of FVIII and D-dimer levels at 1, 3, and 6 months following the COVID infection. Three months after the COVID infection, elevated FVIII was recorded in 44% of younger versus 65% of older individuals, <i>p</i> = 0.05, respectively, and 30 versus 57% (<i>p</i> = 0.008) 6 months post-COVID infection. With a focus on clinical presentation, a higher number of patients with moderate/severe COVID had elevated FVIII activity, but a statistically significant difference was observed only for the 6 months (32% mild vs. 53% moderate/severe, <i>p</i> = 0.041) post-infection time point. Following a COVID infection, an increase in FVIII activity suggests a continued hypercoagulable state in the post-COVID period and correlates with elevated D-dimer levels. This increase in FVIII is more pronounced in patients with moderate/severe clinical picture and those patients older than 50 years.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"490-496"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140013679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}